{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:02:39Z","timestamp":1760821359685,"version":"3.40.5"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may cause severe life-threatening diseases called acute respiratory distress syndrome (ARDS) owing to cytokine storms. The mortality rate of COVID-19-related ARDS is as high as 40% to 50%. However, effective treatment for the extensive release of acute inflammatory mediators induced by hyperactive and inappropriate immune responses is very limited. Many anti-inflammatory drugs with variable efficacies have been investigated. Colchicine inhibits interleukin 1 beta (IL-1\u03b2) and its subsequent inflammatory cascade by primarily blocking pyrin and nucleotide-binding domain leucine-rich repeat and pyrin domain containing receptor 3 (NLRP3) activation. Therefore, this cheap, widely available, oral drug might provide an added benefit in combating the cytokine storm in COVID-19. Here, we sought to determine whether adding colchicine to other standards of care could be beneficial for moderate COVID-19 pneumonia in terms of the requirement for advanced respiratory support and mortality.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods and findings<\/jats:title><jats:p>This blinded placebo-controlled drug trial was conducted at the Dhaka Medical College Hospital, Dhaka, Bangladesh. A total of 300 patients with moderate COVID-19 based on a positive RT-PCR result were enrolled based on strict selection criteria from June 2020 to November 2020. Patients were randomly assigned to either treatment group in a 1:1 ratio. Patients were administered 1.2 mg of colchicine on day 1 followed by daily treatment with 0.6 mg of colchicine for 13 days or placebo along with the standard of care. The primary outcome was the time to clinical deterioration from randomization to two or more points on a seven-category ordinal scale within the 14 days post-randomization. Clinical outcomes were also recorded on day 28. The primary endpoint was met by 9 (6.2%) patients in the placebo group and 4 (2.7%) patients in the colchicine group (P = 0.171), which corresponds to a hazard ratio (95% CI) of 0.44 (0.13\u20131.43). Additional analysis of the outcomes on day 28 revealed significantly lower clinical deterioration (defined as a decrease by two or more points) in the colchicine group, with a hazard ratio [95%CI] of 0.29 [0.098\u20130.917], (P = 0.035). Despite a 56% reduction in the need for mechanical ventilation and death with colchicine treatment on day 14, the reduction was not statistically significant. On day 28, colchicine significantly reduced clinical deterioration measured as the need for mechanical ventilation and all-cause mortality.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Conclusion<\/jats:title><jats:p>Colchicine was not found to have a significant beneficial effect on reducing mortality and the need for mechanical ventilation. However, a delayed beneficial effect was observed. Therefore, further studies should be conducted to evaluate the late benefits of colchicine.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:bold>Clinical trial registration no:<\/jats:bold>ClinicalTrials.gov Identifier: NCT04527562<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.google.com\/search?client=firefox-b-d&amp;q=NCT04527562\" xlink:type=\"simple\">https:\/\/www.google.com\/search?client=firefox-b-d&amp;q=NCT04527562<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0277790","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T18:34:11Z","timestamp":1668623651000},"page":"e0277790","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy of colchicine in patients with moderate COVID-19: A double-blinded, randomized, placebo-controlled trial"],"prefix":"10.1371","volume":"17","author":[{"given":"Motlabur","family":"Rahman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4508-4549","authenticated-orcid":true,"given":"Ponkaj K.","family":"Datta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khairul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2796-2560","authenticated-orcid":true,"given":"Mahfuzul","family":"Haque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reaz","family":"Mahmud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uzzwal","family":"Mallik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1765-8477","authenticated-orcid":true,"given":"Pratyay","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjurul","family":"Haque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imtiaz","family":"Faruq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohiuddin","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rifat H.","family":"Ratul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khan Abul Kalam","family":"Azad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Titu","family":"Miah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4381-1511","authenticated-orcid":true,"given":"Md. Mujibur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"volume-title":"World Health Organization","year":"2020","key":"pone.0277790.ref001"},{"volume-title":"World Health Organization","year":"2020","key":"pone.0277790.ref002"},{"issue":"8","key":"pone.0277790.ref003","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review","volume":"324","author":"WJ Wiersinga","year":"2020","journal-title":"JAMA"},{"issue":"9","key":"pone.0277790.ref004","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamainternmed.2020.3313","article-title":"Is a \u201cCytokine Storm\u201d Relevant to COVID-19?","volume":"180","author":"P Sinha","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"2","key":"pone.0277790.ref005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/jmv.20255","article-title":"An interferon-gamma-related cytokine storm in SARS patients","volume":"75","author":"KJ Huang","year":"2005","journal-title":"J Med Virol"},{"issue":"7","key":"pone.0277790.ref006","doi-asserted-by":"crossref","first-page":"102567","DOI":"10.1016\/j.autrev.2020.102567","article-title":"Should we stimulate or suppress immune responses in COVID- 19? Cytokine and anti-cytokine interventions","volume":"19","author":"Y Jamilloux","year":"2020","journal-title":"Autoimmun Rev"},{"key":"pone.0277790.ref007","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with covid-19","volume":"384","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0277790.ref008","doi-asserted-by":"crossref","first-page":"xxx","DOI":"10.18203\/2349-3259.ijct20210144","article-title":"Efficacy of colchicine in moderate symptomatic COVID-19 patients: a study protocol for a double-blind, randomized, placebo-controlled trial","volume":"8","author":"M Rahman","year":"2021","journal-title":"Int J Clin Trials"},{"key":"pone.0277790.ref009","doi-asserted-by":"crossref","first-page":"108490","DOI":"10.1016\/j.clim.2020.108490","article-title":"Treating COVID-19 with colchicine in community healthcare setting","volume":"217","author":"E Della-Torre","year":"2020","journal-title":"Clin Immunol"},{"issue":"3","key":"pone.0277790.ref010","doi-asserted-by":"crossref","first-page":"e0248276","DOI":"10.1371\/journal.pone.0248276","article-title":"Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study","volume":"16","author":"L Manenti","year":"2021","journal-title":"PLoS ONE"},{"key":"pone.0277790.ref011","doi-asserted-by":"crossref","first-page":"e2013136","DOI":"10.1001\/jamanetworkopen.2020.13136","article-title":"Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial","volume":"3","author":"SG Deftereos","year":"2020","journal-title":"JAMA Netw Open"},{"key":"pone.0277790.ref012","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/annrheumdis-2020-217712","article-title":"Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome","volume":"79","author":"M Scarsi","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"pone.0277790.ref013","doi-asserted-by":"crossref","first-page":"e001455","DOI":"10.1136\/rmdopen-2020-001455","article-title":"Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial","volume":"7","author":"MI Lopes","year":"2021","journal-title":"RMD Open"},{"issue":"10","key":"pone.0277790.ref014","article-title":"Colchicine for the treatment of COVID-19","author":"A Mikolajewska","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"pone.0277790.ref015","unstructured":"National Guidelines on Clinical Management of Coronavirus Disease 2019 (COVID-19).Version 7.0 28 May, 2020, DGHS, MOHFW, Government of the People\u2019s Republic of Bangladesh."},{"journal-title":"Clinical Management of COVID-19, Interim Guidance","year":"2021","author":"World Health Organization, WHO","key":"pone.0277790.ref016"},{"key":"pone.0277790.ref017","unstructured":"World Health Organization,WHO. Coronavirus disease (COVID-2019) R&D. Available at: https:\/\/www.who.int\/blueprint\/priority-diseases\/ key action\/novel-coronavirus\/en\/. [Accessed on: 25 March 2020]."},{"issue":"10","key":"pone.0277790.ref018","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/infdis\/jiz656","article-title":"Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection","volume":"221","author":"Y Wang","year":"2020","journal-title":"J Infect Dis"},{"key":"pone.0277790.ref019","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of Lopinavir Ritonavir in Adults Hospitalized with Severe Covid- 19","volume":"382","author":"B Cao","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0277790.ref020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/2229-3485.71856","article-title":"Sample Size Estimation in Clinical Trial","volume":"1","author":"TV Sakpal","year":"2010","journal-title":"Perspect Clin Res"},{"issue":"5","key":"pone.0277790.ref021","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3390\/jcm9051548","article-title":"Early Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19 Infection in Lombardy, Italy","volume":"9","author":"M Cecconi","year":"2020","journal-title":"Journal of Clinical Medicine"},{"journal-title":"Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19","year":"2021","author":"JC Tardif","key":"pone.0277790.ref022"},{"key":"pone.0277790.ref023","article-title":"Colchicine use in patients with COVID-19: a systematic review and meta-analysis","author":"L Chiu","year":"2021","journal-title":"medRxiv"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0277790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T13:15:21Z","timestamp":1728393321000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0277790"}},"subtitle":[],"editor":[{"given":"James","family":"Mockridge","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0277790","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2022,11,16]]}}}